SARS-CoV-2 Delta (B.1.617.2) variant of concern (VOC) and other VOCs are spreading in Europe. Micro-neutralisation assays with sera obtained after Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in 36 healthcare workers (31 female) demonstrated significant fold change reduction in neutralising titres compared with the original virus: Gamma (P.1) 2.3, Beta (B.1.351) 10.4, Delta 2.1 and 2.6. The reduction of the Alpha (B.1.1.7) variant was not significant. Despite being lower, remaining neutralisation capacity conferred by Comirnaty against Delta and other VOCs is probably protective.
|State||Published - 1 Jul 2021|
Bibliographical noteFunding Information:
We wish to dedicate this study to all persons from the ministries of Health, Foreign Affairs and Defense who played a key role in the epidemiological investigations and retrieval of clinical samples for sequencing and culturing. Without their dedication and efforts this study could not have been conducted. YL is supported by the Nehemia Rubin Excellence in Biomedical Research – The TELEM Program of Chaim Sheba Medical Center. We thank Profs. Ester Cerdeira Sabino and Maria Cassia Mendes Correa from the Tropical Medicine Institute, University of São Paulo, São Paulo, Brazil for kindly providing us the Gamma variant (P.1) isolate.
© 2021 European Centre for Disease Prevention and Control (ECDC). All rights reserved.